Year: 2020

news_6

 Hansoh Pharma’s AMEILE (almonertinib) Receives Marketing Authorization in China for Second-line Treatment for Patients With EGFR T790m-mutation Non-small Cell Lung Cancer

SHANGHAI--(BUSINESS WIRE)--Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, announced that the National Medical Products...